Pfizer, Merck & Co., Eli Lilly and Co. and PureTech Ventures, a venture-capital firm, have collaborated to form Enlight Biosciences, a for-profit undertaking aimed at developing technologies to speed up drug discovery while decreasing the failure rate of clinical studies. Enlight will spin off firms focused on a promising technology and might look into areas including cell-line production and techniques to administer treatments across the blood-brain barrier.

Related Summaries